Holen Sie sich die Stockscreener-App
3.53
0.00%
0.00
Handel nachbörslich:
3.42
-0.11
-3.12%
Schlusskurs vom Vortag:
$3.53
Offen:
$3.52
24-Stunden-Volumen:
215.87K
Relative Volume:
0.52
Marktkapitalisierung:
$35.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1795
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
-1.40%
1M Leistung:
+26.07%
6M Leistung:
+16.12%
1J Leistung:
-16.75%
1-Tages-Spanne:
$3.42
$3.58
1-Wochen-Bereich:
$3.42
$3.74
52-Wochen-Spanne:
$2.30
$4.42
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.53 | 35.67M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating - MarketScreener
Roth Capital Adjusts PolyPid (PYPD) Price Target Amid New Financing | PYPD Stock News - GuruFocus
PolyPid (NASDAQ:PYPD) Given New $14.00 Price Target at JMP Securities - Defense World
PYPD: JMP Securities Lowers Price Target While Maintaining Marke - GuruFocus
PolyPid (PYPD) Price Target Adjusted Amid Financing Developments - GuruFocus
PolyPid stock price target lowered to $14 at JMP on warrant dilution By Investing.com - Investing.com South Africa
PolyPid stock price target lowered to $14 at JMP on warrant dilution - Investing.com Australia
PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial - TipRanks
Citizens JMP Adjusts Price Target for PolyPid (PYPD) Amid Warrant Developments | PYPD Stock News - GuruFocus
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire Inc.
FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PESG Research Update: PolyPid SHIELD’s II Delivers - GlobeNewswire
PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline ResultsParadigm Shift in Surgical Infection Prevention - Yahoo
In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed - insights.citeline.com
HC Wainwright Issues Positive Forecast for PolyPid (NASDAQ:PYPD) Stock Price - Defense World
PolyPid reports positive phase 3 surgical infection drug trial - גלובס
PolyPid (PYPD) Target Price Increased as Phase 3 Trial Data Impr - GuruFocus
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial - Benzinga
PolyPid shares surge on successful D-PLEX100 trial results By Investing.com - Investing.com South Africa
PolyPid shares surge on successful D-PLEX100 trial results - Investing.com Australia
Transcript : PolyPid Ltd.Special Call - MarketScreener
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - The Manila Times
PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial - marketscreener.com
PolyPid (PYPD) Reports Positive Phase 3 Trial Results for D-PLEX100 | PYPD Stock News - GuruFocus
PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial - TipRanks
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewswire
What is Roth Capital’s Forecast for PolyPid Q2 Earnings? - Defense World
Roth Capital Begins Coverage on PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - The Manila Times
PolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100 - Nasdaq
PolyPid to Host Conference Call and Webcast to Discuss - GlobeNewswire
Major Clinical Trial Results: PolyPid's D-PLEX100 Shows New Data for Preventing Post-Surgery Infections - Stock Titan
Roth Capital Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - Nasdaq
Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rat - GuruFocus
Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rating | PYPD Stock News - GuruFocus
Roth Capital Initiates PolyPid at Buy With $9 Price Target - marketscreener.com
PolyPid initiated with a Buy at Roth Capital - TipRanks
What is HC Wainwright’s Forecast for PolyPid Q2 Earnings? - Defense World
FY2027 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Upgraded by HC Wainwright to “Buy” Rating - Defense World
PolyPid (NASDAQ:PYPD) Now Covered by HC Wainwright - Defense World
Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout - newsblaze.com
PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Through Clinical Trials to Improve Surgical Outcomes, Enhance Treatment Efficacy, Minimize Side Effects - Yahoo Finance
H.C. Wainwright assumes coverage on PolyPid stock with buy rating - Investing.com
PolyPid assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright assumes coverage on PolyPid stock with buy rating By Investing.com - Investing.com India
PolyPid (PYPD) Receives a 'Buy' Rating from HC Wainwright & Co. - GuruFocus
H.C. Wainwright Initiates Buy Coverage on PolyPid (PYPD) with $1 - GuruFocus
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - Defense World
PolyPid Expands Share Option Plan to Boost Stakeholder Engagement - TipRanks
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):